newsfilter
← Latest News
GlobeNewswire·

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

VERU
  • Veru Inc. announced that Chairman, President & CEO Mitchell Steiner, M.D. will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York City on September 9, 2026, from 2:10 pm to 2:40 pm ET.
  • A live webcast of the event will be available via the Investors section of Veru's website at www.verupharma.com, with an archived version accessible afterward.
  • Veru is a late clinical stage biopharmaceutical company developing enobosarm & sabizabulin for cardiometabolic & inflammatory diseases.
  • Enobosarm is an oral selective androgen receptor modulator (SARM) designed to enhance weight reduction by GLP-1 RA drugs by selectively reducing fat while preserving lean mass, physical function, & bone mineral density.
  • Sabizabulin is a microtubule disruptor being developed to treat chronic inflammation related to atherosclerotic cardiovascular disease.
  • The Phase 2b PLATEAU clinical study evaluating enobosarm 3mg combined with semaglutide in older patients with obesity has fully enrolled 239 patients, exceeding the target of 200.
  • The PLATEAU study aims to assess if enobosarm helps break through weight loss plateaus observed with GLP-1 RA therapy by preserving muscle mass & physical function over 68 weeks.
  • Interim analysis results for lean body mass & fat mass from the PLATEAU study are expected in Q1 2027, with final topline data expected in Q4 2027.
  • Dr. Steven Heymsfield serves as the Principal Investigator for the Phase 2b PLATEAU clinical trial.
  • The Phase 2b QUALITY clinical study was positive, demonstrating that enobosarm plus semaglutide preserved lean mass & physical function while increasing fat loss during the active period.
  • The QUALITY maintenance extension showed that enobosarm monotherapy prevented weight regain & continued fat loss after semaglutide treatment was discontinued.
  • Veru plans to prioritize internal cash for the PLATEAU Phase 2b trial, meaning sabizabulin advancement will depend on securing additional funding.
  • The press release includes forward-looking statements regarding trial designs, enrollment, data readouts, regulatory pathways, & potential partnership opportunities for enobosarm & sabizabulin.
  • Risks identified include potential FDA disagreements on trial designs, funding constraints, termination of the Novo Nordisk supply agreement, & competition from other obesity therapies.